fosaprepitant / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 63 Diseases   25 Trials   25 Trials   493 News 


«1234567»
  • ||||||||||  dexamethasone / Generic mfg., amisulpride / Generic mfg.
    Retrospective data, Review, Journal:  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis. (Pubmed Central) -  Jun 22, 2021   
    Granisetron and amisulpride are likely to have little or no increase in any adverse event compared with placebo, while dimenhydrinate and scopolamine may increase the number of patients with any adverse event compared with placebo...There is convincing evidence regarding the prophylactic effect of at least seven single drugs for postoperative vomiting such that future studies investigating these drugs will probably not change the estimated beneficial effect. However, there is still considerable lack of evidence regarding safety aspects that does warrant investigation.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
    [VIRTUAL] Venous Irritation Resulting from IV Fosaprepitant: A Systematic Review of Evidence () -  Mar 12, 2021 - Abstract #ONS2021ONS_457;    
    Fosaprepitant-induced peripheral venous irritation (PVI) among patients receiving certain chemotherapy regimens, particularly Adriamycin, leads to delays in treatment, wasted resources, additional medical intervention, and patient dissatisfaction...Commentary and tutorial articles suggest switching to oral aprepitant or administration via a central line, but do not cite clinical evidence to support these recommendations...Clinical trials are needed to determine the comparative effectiveness. When the results of those trials are available, guidelines should be updated to guide practice.
  • ||||||||||  Clinical, Journal:  A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin. (Pubmed Central) -  Mar 5, 2021   
    Olanzapine is an active agent against CINV and may offer better control of nausea compared to aprepitant/fosaprepitant-based regimens...Methods We used a modified regimen "mini-OPD", oral olanzapine (5 mg) days 1 and 2, intravenous palonosetron (0.25 mg) and dexamethasone (12 mg) on day 1 of cisplatin administration in patients with carcinoma of the cervix receiving concurrent chemoradiotherapy with weekly cisplatin (40 mg/m/week)...There were no significant side effects. Conclusions The mini-OPD regimen is an inexpensive, non-toxic and effective regimen for the prevention of CINV in patients receiving weekly cisplatin concurrent with pelvic radiotherapy.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Antiemetics: ASCO Guideline Update. (Pubmed Central) -  Feb 26, 2021   
    There is no clinical evidence to warrant omission of dexamethasone from guideline-compliant prophylactic antiemetic regimens when CPIs are administered to adults in combination with chemotherapy. CPIs administered alone or in combination with another CPI do not require the routine use of a prophylactic antiemetic.Additional information is available at www.asco.org/supportive-care-guidelines.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
    [VIRTUAL] Adherence to national antiemetic guidelines at a community cancer center: a retrospective study. () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_3026;    
    Inappropriate treatment was predominantly due to undertreatment, particularly those with highly emetogenic chemotherapy not receiving olanzapine prophylaxis. Treatment failures requiring a return visit to the cancer center were infrequent and rarely due to inappropriate antiemetic prophylaxis (2.1% of patients).
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
    Journal:  Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. (Pubmed Central) -  Dec 2, 2020   
    The incidence of HSRs to fosaprepitant at our institution was found to be consistent with the <1% incidence currently noted in literature. Based on these findings, opportunities have been identified for education on fosaprepitant-associated HSRs, proper documentation and patient-specific precautions.
  • ||||||||||  Varubi (rolapitant oral) / TerSera Therap, GSK
    Retrospective data, Review, Journal:  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. (Pubmed Central) -  Nov 18, 2020   
    No further efficacy studies are needed as there is evidence of moderate to high certainty for seven single drugs with relevant benefit for prevention of vomiting. However, additional studies are needed to investigate potential side effects of these drugs and to examine higher-risk patient populations (e.g. individuals with diabetes and heart disease).
  • ||||||||||  carboplatin / Generic mfg., olanzapine / Generic mfg., paclitaxel / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (clinicaltrials.gov) -  Nov 2, 2020   
    P3,  N=170, Not yet recruiting, 
    Induration may be prevented by selecting larger diameter vessels using ultrasonography when catheterizing for chemotherapy. Trial completion date: Sep 2022 --> Dec 2022 | Initiation date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Novartis, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Clinical, Journal:  Potential cross-reactivity of polysorbate 80 and cremophor: A case report. (Pubmed Central) -  Oct 28, 2020   
    It is well documented that paclitaxel and fosaprepitant have the potential to cause hypersensitivity reactions due to their excipients. While it is likely that each reaction was a unique event, it is difficult to ignore the possibility of cross-reactivity due to the presence of oleic acid in both excipients.
  • ||||||||||  dexamethasone / Generic mfg., carboplatin / Generic mfg., fosaprepitant / Generic mfg.
    Trial completion date, Trial primary completion date:  Low Dose Aprepitant for Patients Receiving Carboplatin (clinicaltrials.gov) -  Sep 30, 2020   
    P2,  N=50, Recruiting, 
    Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Jul 2020 --> Aug 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
  • ||||||||||  Varubi (rolapitant oral) / TerSera Therap, GSK
    Trial termination:  Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) -  Jul 16, 2020   
    P2,  N=37, Terminated, 
    The developed population PK model adequately described aprepitant PK across a broad pediatric population, justifying fixed (adult) dosing for adolescents and weight-based dosing of oral aprepitant for children. Completed --> Terminated; Terminated per PI's request
  • ||||||||||  Varubi (rolapitant oral) / TerSera Therap, GSK
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) -  Jul 14, 2020   
    P2,  N=37, Completed, 
    Completed --> Terminated; Terminated per PI's request Recruiting --> Completed | N=91 --> 37 | Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
    Journal:  The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications. (Pubmed Central) -  May 15, 2020   
    With a preference to small non-peptidic ligands, many research groups invested efforts in synthesizing and evaluating a wide range of scaffolds, but only the NK1 antagonist Aprepitant (EMENDT) and its prodrug Fosaprepitant (IVEMENDT) have been approved by the Food Drug Administration (FDA) for the treatment of Chemotherapy-Induced and Post-Operative Nausea and Vomiting (CINV and PONV, respectively)...Various strategies were implemented to modulate affinity, selectivity and activity of the newly designed ligands. Replacement of canonical amino acids, incorporation of conformational constraints, and fusion with non-peptidic moieties gave rise to families of ligands displaying individual or dual NK1, NK2 and NK3 antagonism, that ultimately was combined with non-neurokinin ligands (such as opioids) to target enhanced biological impact.